2007 Top 10 Biopharmaceutical Companies Report

Warts and all, Amgen remains at the apex of the Top 10 Biopharma rankings. The first half of 2007 was none too kind to the top gun, but Amgen still has a comfortable lead over its competitors on this list.

Speaking of which, there are a pair of new entries at #3 and #4! After putting Novo Nordisk on the Top 20 Pharma list last year, I decided that it would be more suited to the Top Biopharma ranks, especially since it announced that it was closing down all small molecule R&D. And UCB Group made its way onto our list after last year’s edition came out and members of the company called to explain (patiently) why UCB should truly be considered a Biopharma (a lot of companies misuse the term, in my opinion). Their argument made enough sense for me to add them to this year’s ranks.

Also, Chiron dropped from the list after being bought by Novartis. Serono and MedImmune will follow suit in next year’s edition.

—Gil Y. Roth, Editor

 

Top 10 Biopharmaceutical Companies
01	Amgen	$13,858
02	Genentech	$7,640
03	Novo Nordisk	$6,526
04	UCB Group	$2,711
05	Biogen Idec	$2,592
06	Gilead Sciences	$2,588
07	Serono	$2,498
08	Genzyme	$2,278
09	MedImmune	$1,221
10	Millennium	$220

Based on 2006 biopharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the online edition, pipeline and patent expiry info is only available for companies #1-3.

 

Contributors

Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth.

 

All pipeline information compiled by Kristin Brooks